Navigation Links
Analyses Find Type 2 Diabetes Patients Treated with BYDUREON™ Experienced Reduction in Cardiovascular Risk Factors: Results Presented at EASD 2011
Date:9/12/2011

vs. Lantus; treatment difference: 9.8 pounds).  

Also, statistically significantly more patients in the BYDUREON treatment arm:

  • Met a composite endpoint of A1C <7 percent plus target systolic blood pressure (<130 mmHg) and LDL cholesterol (<100 mg/dL) (15.7 percent vs. 7.9 percent with Lantus); and
  • Met a composite endpoint of A1C less than or equal to 6.5 percent plus target systolic blood pressure (<130 mmHg) and LDL cholesterol (<100 mg/dL) (11.2 percent vs. 5.1 percent with Lantus).

  • Drug-naive patients with type 2 diabetes participating in the DURATION-4 trial were randomized to one of four treatment arms: BYDUREON, metformin, Actos® (pioglitazone HCI) and Januvia® (sitagliptin). The post-hoc analyses showed patients treated with BYDUREON or metformin were more likely to achieve clinically relevant composite goals than patients treated with Actos or Januvia. Researchers evaluated how many patients in each treatment group:

  • Achieved a composite endpoint of A1C <7 percent, no weight gain and no minor or major hypoglycemia (48 percent for BYDUREON vs. 22 percent for Actos, 35 percent for Januvia and 46 percent for metformin); and
  • Reached a composite endpoint of A1C <7 percent plus target systolic blood pressure (<130 mmHg) and target LDL cholesterol (<100 mg/dL) (16 percent for BYDUREON vs. 10 percent for Actos, 7 percent for Januvia and 13 percent for metformin).

  • In the DURATION-3 study, gastrointestinal adverse events were among those most commonly reported; however, the number of new cases of all adverse events declined during the extension phase of the trial. In the DURATION-4 study, the most frequently reported adverse events among BYDUREON users were nausea and diarrhea. These data are consistent with the previously reported profiles of BYDUREON and BYETTA® (exenatide) injection.

    BYDUREON is the proposed brand name for exenatide extended-r
    '/>"/>

    SOURCE Amylin Pharmaceuticals, Inc.; Eli Lilly and Company; Alkermes, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9

    Related medicine technology :

    1. Four Analyses of Three-Year Clinical Data Suggest CYPHER(R) Sirolimus-Eluting Coronary Stent May Provide Alternative to Surgery for Patients with Multivessel Disease
    2. Xeloda XeNA Study Analyses of Xeloda, Docetaxel and Herceptin Combination Therapy for Metastatic Breast Cancer Featured at Major New Breast Cancer Symposium
    3. Xeloda(R) XeNA Study Analyses of Xeloda, Docetaxel and Herceptin Combination Therapy for Metastatic Breast Cancer Featured at Major New Breast Cancer Symposium
    4. Interim Response and Safety Analyses Support Continuation of Allos Therapeutics Pivotal Phase 2 PROPEL Trial of PDX in Patients with Peripheral T-Cell Lymphoma
    5. New Analyses of Long-Term LIALDA(TM) (mesalamine) Data Presented at ACG
    6. New MIRCERA(R) Data Analyses to be Featured at the American Society of Nephrology Annual Meeting
    7. New Analyses Presented at ASCO Reaffirmed Efficacy and Safety of TORISEL in Patients With Advanced Kidney Cancer
    8. Preliminary Analyses from Phase 2 Genzyme Study Highlight Efficacy and Safety of Clofarabine in Older Adult AML Patients
    9. Independent Analyses of the SEAS, SHARP and IMPROVE-IT Studies of Ezetimibe
    10. New Analyses Indicate that Divigel(R) (estradiol gel) 0.1% Is a Valuable Option for Certain Postmenopausal Women With Hot Flashes
    11. Results and Additional Analyses From Efficacy and Safety Study of Cortheras Relaxin in Acute Heart Failure to be Presented at Heart Failure Congress 2009
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:12/24/2014)... N.Y. , Dec. 24, 2014 Kinex ... dosed with KX2-361 at Roswell Park Cancer Institute. ... small molecule drug that has shown potent inhibitory activity ... including those that are resistant to Temozolomide (T98G), the ... glioma. In a well-established brain tumor mouse model, KX2-361 ...
    (Date:12/24/2014)... and FARMINGTON, Conn. , Dec. ... MKT: PTN), a biopharmaceutical company developing targeted, receptor-specific ... significant unmet medical need and commercial potential, today ... placement of 2,050,000 shares of its common stock ... of its common stock.  Funds under the management ...
    (Date:12/24/2014)... , Dec. 23, 2014 ResMed (NYSE: ... patent infringement action against Chinese medical device manufacturer BMC Medical ... ruled today that BMC,s masks listed below infringe ResMed,s patents, ... selling these masks in the United States ... N2 nasal mask , Willow nasal pillows mask ...
    Breaking Medicine Technology:Kinex Pharmaceuticals Announces First Patient Dosed with KX2-361 in a Phase 1 Clinical Study 2Kinex Pharmaceuticals Announces First Patient Dosed with KX2-361 in a Phase 1 Clinical Study 3Palatin Completes $20 Million Equity and $10 Million Debt Financings 2Palatin Completes $20 Million Equity and $10 Million Debt Financings 3Palatin Completes $20 Million Equity and $10 Million Debt Financings 4ResMed Wins Patent Infringement Lawsuit Against Chinese Manufacturer BMC Medical 2
    ... Biodesix announces the enrollment of initial subjects into ... Medical Institute (ALCMI, pronounced as "Alchemy"). The CASTLE (Collaborative ... minimum of 250 subjects over two years among academic ... study collects biospecimens and data from lung cancer patients ...
    ... / PRNewswire / -- Unilife Corporation ("Unilife" or ... announced that it will be presenting at Deutsche Bank,s 36th ... Alan Shortall, Chief Executive Officer of Unilife, is scheduled to ... The conference presentation will be broadcast over the ...
    Cached Medicine Technology:Biodesix Supports Unique Lung Cancer Research Initiative 2Biodesix Supports Unique Lung Cancer Research Initiative 3Unilife to Present at the 36th Annual Deutsche Bank Health Care Conference on Monday, May 2, 2011 in Boston 2
    (Date:12/25/2014)... December 26, 2014 The report “TS-1 ... focuses on the current treatment landscape, unmet needs, current ... TS-1 is an anti-cancer drug which is typically used ... is also used for treating gastric cancer and pancreatic ... potassium. The drug was first approved in 1999 in ...
    (Date:12/25/2014)... 2014 Recently, Dylan Queen, a famous ... released its collection of discounted prom dresses, most of ... senior spokesman of the company, the promotion is valid ... is to expand the UK market. , The prom ... colors, lengths, and styles: A-line strapless, empire strapless chiffon, ...
    (Date:12/25/2014)... Woodland Hills, California (PRWEB) December 25, 2014 ... in her home in Woodland Hills, California after an ... Harris passed away on Christmas Eve evening in her ... battle with aggressive metastatic breast cancer. ... International for over forty years, she pioneered and championed ...
    (Date:12/25/2014)... 25, 2014 (HealthDay News) -- The risk of burns ... so you need to be extra cautious, an expert ... see a significant increase in patients coming in with ... Suffolk County Volunteer Firefighters Burn Center of Stony Brook ... be full of joy, but if not careful, could ...
    (Date:12/25/2014)... 25, 2014 AngelWeddingDress.com tries its best ... online realm. Today, the business has introduced its new ... prom dress promotion. , The new prom outfits are ... every dress lover. They are specially designed for 2015. ... dresses should visit its website before Jan. 26, ...
    Breaking Medicine News(10 mins):Health News:TS-1 Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 2Health News:TS-1 Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 3Health News:Dylan Queen: Cheap Prom Dresses for the UK Market 2Health News:RP International founder, Helen Harris Dies on Christmas Eve Just Hours Before Her Holiday Television Broadcast to Raise Funds to Cure Blindness was Broadcasted Nationally 2Health News:RP International founder, Helen Harris Dies on Christmas Eve Just Hours Before Her Holiday Television Broadcast to Raise Funds to Cure Blindness was Broadcasted Nationally 3Health News:RP International founder, Helen Harris Dies on Christmas Eve Just Hours Before Her Holiday Television Broadcast to Raise Funds to Cure Blindness was Broadcasted Nationally 4Health News:Don't Let Burns Mar Your Holidays 2Health News:Angelweddingdress 2015 Prom Dresses Online Now 2
    ... drug maker, Pfizer has announced that it intends to fast ... approvals from the US Food and Drug Administration // ... developed in collaboration with Sanofi-Aventis and Nektar Therapeutics. ... no needles or pens or syringes are needed. "Until today, ...
    ... which are also said to be connected to cancer. As ... them were seen to contain halogen organic compounds which may ... Oeko-Test. ,Perfumes found in six of the ... natural protection mechanisms of the skin, was detected in some ...
    ... patient has successfully reached the Vinson Massif summit, one ... January 12th and was successfully completed on January 19th ... ,He was a strong, healthy athlete who was ... the course of the disease he lost 80 pounds ...
    ... Pharmaceuticals have come out with a new experimental Microbicide PRO ... and the herpes simplex virus. The findings of the study ... ,Microbicides are products such as gels, films and sponges ... and other sexually transmitted diseases. , Betsy Herold ...
    ... of stress on the pregnant women. ... stress and people are in search for a remedy for it. // ... number of pregnant women approaching the health care centers for a treatment ... a need to include new information about the management of stress during ...
    ... are being raised with regard to the real danger posed by ... Turkey while others infected in the country have // survived. Most ... has been grossly overrated. The death toll rate of the H5N1 ... Dr. Guenael Rodier has however called upon scientists not draw conclusions ...
    Cached Medicine News:Health News:Crohn's Patient Robert Hill’s greatest achievemen 2
    ... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
    ... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
    ... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
    ... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
    Medicine Products: